HaiXin Rhett Biomedical Technology Co., Shanghai, starts pilot-scale production of recombinant human serum albumen in Shanghai

The company has developed technology for production and purification to injection-grade hSA in the lab scale. A pilot plant for production will now be established at Shanghai’s Zhangjiang Center for Biomedicine Development.

Science Daily, Oct. 15, 2012

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny